Clinical Trial Update: A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating CyBorD (cyclophosphamide, bortezomib, dexamethasone) plus daratumumab in people with Monoclonal Gammopathy of Renal Significance (MGR…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Monoclonal Gammopathy of Renal Significance
• Multiple Myeloma

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• Cyclophosphamide (Cytoxan) (cyclophosphamide)
• DEXAMETHASONE (Dexamethasone)
• Daratumumab (Darzalex) (daratumumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma, Monoclonal Gammopathy of Renal Significance | Phase 2 | Status: RECRUITING